SLC5A2 and stroke disorder: The two groups did not show significant differences in age, sex, history of smoking or alcohol consumption, hypertension, CVD, stroke, antihypertensive drugs, lipid-lowering treatment (statins, fenofibrate), antiplatelet therapy, antidiabetic drugs (insulin, TZD, AGI, SU, DPP-4i, GLP-1 Ras, Met, SGLT2-i), duration, BMI, SBP, DBP, or most laboratory parameters (P > 0.05).